Two Sigma Securities’s Biolase, Inc. BIOL Stock Holding History

Two Sigma Securities’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,609	Closed	-$11.4K	–	3611
2023 Q2	$11.4K	Buy	+1,609	New	+$26.9K	﹤0.01%	2578
2023 Q1	–	Sell	-111	Closed	-$7.24K	–	3433
2022 Q4	$7.24K	Buy	+111	New	+$16K	﹤0.01%	2411
2022 Q2	–	Sell	-6	Closed	-$5K	–	2953
2022 Q1	$5K	Sell	6 -6	-50%	-$5.54K	﹤0.01%	2064
2021 Q4	$12K	Hold	12	–	–	﹤0.01%	1463
2021 Q3	$19K	Buy	+12	New	+$19.6K	﹤0.01%	1465
2019 Q1	–	Sell	-5	Closed	-$12K	–	2558
2018 Q4	$12K	Buy	+5	New	+$16.1K	﹤0.01%	2003
2018 Q3	–	Sell	-5	Closed	-$15K	–	3121
2018 Q2	$15K	Buy	+5	New	+$18.8K	﹤0.01%	2571
2017 Q4	–	Sell	-3	Closed	-$20K	–	2072
2017 Q3	$20K	Buy	+3	New	+$25.9K	﹤0.01%	828
2016 Q2	–	Sell	-1	Closed	-$15K	–	543
2016 Q1	$15K	Buy	+1	New	+$12.5K	0.02%	249

Other funds holding BIOL

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Securities's BIOL Position: Q3 2023 in Review

Two Sigma Securities sold out of Biolase, Inc. (BIOL) in Q3 2023, closing a stake of 1,609 shares — an estimated $11.4K sold.

Two Sigma Securities first reported a position in BIOL in Q1 2016 and held it in 9 quarters. The position peaked at $20K in Q3 2017. 12 funds tracked by Wall St. Rank hold BIOL as of Q3 2023.

Two Sigma Securities reported no remaining Biolase, Inc. position as of Q3 2023 after selling out during the quarter.
Two Sigma Securities sold 1,609 Biolase, Inc. shares in Q3 2023, an estimated $11.4K.
Two Sigma Securities first reported a position in Biolase, Inc. in Q1 2016 and held it in 9 quarters.
Two Sigma Securities's Biolase, Inc. position peaked at $20K in Q3 2017.
12 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.